• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bright Minds Biosciences Inc. - common stock (NQ: DRUG )

    1.270 -0.090 (-6.62%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Aug 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 225,281
    Open 1.230
    Bid (Size) 1.200 (11)
    Ask (Size) 1.270 (14)
    Prev. Close 1.360
    Today's Range 1.180 - 1.290
    52wk Range 0.9300 - 2.640
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts
    Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders. 
    Via Benzinga
    DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
    Bright Minds Biosciences just reported results for the third quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -30.93%
    -30.93%
    1 Month
    +10.43%
    +10.43%
    3 Month
    +0.60%
    +0.60%
    6 Month
    -31.72%
    -31.72%
    1 Year
    -47.08%
    -47.08%

    More News

    Read More
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024
    Via InvestorPlace
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
    Via Benzinga
    Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
    Via Benzinga
    Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
    Via Benzinga
    Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
    Via Benzinga
    Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
    Via Benzinga
    Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
    Via Benzinga
    Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
    Via Benzinga
    Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
    Via Benzinga
    Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
    Via Benzinga
    Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
    Via Benzinga
    Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
    Via Benzinga
    Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
    Via Benzinga
    Exposures Product Safety
    Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More
    Via Benzinga
    Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.